Business context and reporting period
The supplied filing is Athira Pharma, Inc.’s Form 10-K for the fiscal year ended December 31, 2023, filed February 22, 2024—not a filing identified as Leonabio, Inc. The company is a clinical-stage biopharmaceutical developer with no approved products or product-sales revenue. Its lead candidate, fosgonimeton, targets mild-to-moderate Alzheimer’s disease (AD); other programs include ATH-1105 for ALS and ATH-1020.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $93.8 million | $61.5 million |
| General and administrative expense | $33.3 million | $32.6 million |
| Operating expenses, net of insurance recovery | $125.5 million | $104.0 million |
| Net loss | $117.7 million | $95.6 million |
| Net loss per share, basic and diluted | $3.09 | $2.53 |
| Net cash used in operating activities | $100.8 million | $72.5 million |
Research and development spending rose 53%, principally due to fosgonimeton trial, extension-study and manufacturing activity. Net loss also increased, partly reflecting higher operating costs and lower NIH grant income; higher investment income partially offset these factors. No meaningful operating margin is reported given the absence of product revenue.
At year-end, cash and cash equivalents were $90.6 million and investments were $56.8 million, totaling $147.4 million. Current assets were $154.7 million and current liabilities $28.8 million. Total liabilities were $30.1 million, chiefly accrued expenses, the $10.0 million accrued legal settlement and operating lease obligations; the filing does not report borrowings. Management estimates year-end cash, cash equivalents and investments will fund operations and capital needs for at least 12 months after the filing date, but says substantial additional funding will be required over time. A $75 million at-the-market equity facility was available, with no shares sold under it as of the filing.
Audited financial statements received an unqualified opinion from Ernst & Young. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation. Cash flows included $95.1 million provided by investing activities, largely from investment maturities, and $0.5 million provided by financing activities, mainly employee stock-plan proceeds.
Material changes and operating developments
- ACT-AD’s primary and secondary endpoints were not met under the prespecified analyses. Favorable subgroup and biomarker observations were post hoc and are not proof of efficacy.
- The 28-participant SHAPE trial in Parkinson’s disease dementia and dementia with Lewy bodies also missed its primary endpoint. Directionally positive findings at 40 mg came from a very small modified-intent-to-treat subgroup; 70 mg results were inconsistent.
- LIFT-AD was amended to focus on participants not taking background acetylcholinesterase inhibitors and on the 40 mg dose. Enrollment was completed in January 2024 at approximately 318 participants; topline results were expected in the second half of 2024.
- ATH-1020 completed its single-ascending-dose Phase 1 escalation and was described as well tolerated in healthy volunteers. Further development remained under consideration.
- ATH-1105 remained preclinical. The company planned to submit an IND and begin Phase 1 testing in the first half of 2024.
Outlook, risks, contingencies and unusual items
The company expects continued operating losses and no near-term product revenue. Its outlook depends heavily on LIFT-AD results, regulatory feedback, financing access and the ability to develop and commercialize candidates. The FDA emphasized that LIFT-AD should demonstrate effects on both cognition and function; FDA approval is not assured, and further trials may be required.
Key risks include clinical failure, uncertain translation of animal and biomarker results, dependence on third-party manufacturers and trial operators, competition, and the need for additional capital. The filing highlights a special committee’s finding that former CEO Leen Kawas altered images in her dissertation and at least four research papers; WSU’s review remained ongoing. The company states that WSU’s dihexa patent, exclusively licensed to Athira, incorporated certain altered images. DOJ and SEC investigations were also ongoing, and related securities and derivative litigation remained a risk.
A proposed $10.0 million securities class-action settlement was accrued in 2022. Athira recorded a $1.6 million insurance recovery in 2023. As of February 15, 2024, the court had preliminarily approved the proposed settlement, with further approval steps outstanding. The filing also reports a $0.9 million contingent milestone commitment under the WSU license, plus potential royalties and sublicense payments. NIH grant income was exhausted: cumulative recognized income reached $15.2 million, with no additional grant income expected.
Important facts for investors to verify
- Confirm the issuer and filing: the supplied document is Athira Pharma’s 2023 Form 10-K, not a Leonabio filing.
- Review final LIFT-AD results and the trial’s prespecified population, endpoint analyses and safety data against the stated second-half 2024 timeline.
- Track cash burn, available cash and investments, financing activity, and whether the stated runway assumptions remain valid.
- Follow final court approval and payment details for the proposed settlement, insurance recovery, derivative litigation, and DOJ and SEC investigations.
- Assess WSU’s research-misconduct review and any resulting effect on licensed intellectual property, grants, regulatory standing or corporate reputation.